ribavirin has been researched along with idx184 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Box, T; Chen, J; Dejesus, E; Dubuc-Patrick, G; Godofsky, E; Kwo, P; Lalezari, J; Lawrence, S; Mayers, D; McCarville, J; Mehra, P; Nguyen, T; O'Riordan, W; Pietropaolo, K; Poordad, F; Sullivan-Bólyai, J; Zhou, XJ | 1 |
| Bilello, JP; Chapron, C; Gillum, JM; La Colla, M; Lallos, LB; McCarville, JF; Pierra, C; Seifer, M; Serra, I; Standring, DN | 1 |
| Elfiky, AA | 1 |
1 trial(s) available for ribavirin and idx184
| Article | Year |
|---|---|
IDX184 in combination with pegylated interferon-α2a and ribavirin for 2 weeks in treatment-naive patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Female; Genotype; Guanosine Monophosphate; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2013 |
2 other study(ies) available for ribavirin and idx184
| Article | Year |
|---|---|
In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cell Line; Dose-Response Relationship, Drug; Drug Resistance, Viral; Drug Synergism; Gene Expression Regulation, Viral; Genotype; Guanosine Monophosphate; Hep G2 Cells; Hepacivirus; Humans; Interferon-alpha; Mutation; Replicon; Ribavirin; Viral Nonstructural Proteins; Virus Replication | 2014 |
Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.
Topics: Adenosine Monophosphate; Alanine; Alphacoronavirus; Amino Acid Sequence; Antiviral Agents; Betacoronavirus; Catalytic Domain; Computational Biology; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Guanosine Monophosphate; Guanosine Triphosphate; Humans; Molecular Docking Simulation; Pneumonia, Viral; Protein Binding; Protein Conformation, alpha-Helical; Protein Conformation, beta-Strand; Protein Interaction Domains and Motifs; Ribavirin; RNA-Dependent RNA Polymerase; SARS-CoV-2; Sequence Alignment; Sequence Homology, Amino Acid; Sofosbuvir; Thermodynamics; Uridine Triphosphate; Viral Proteins | 2020 |